Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.

Enormous progress has been made in tackling the global HIV epidemics over the past two decades. The number of people dying ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research published in The Lancet medical journal. The drug lenacapavir passed a critical ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

SAN FRANCISCO -- At least 400 researchers, physicians, activists, and other concerned citizens gathered here Monday night to ...